Skip to content

SankoreAfrican research intelligence

Countries
Institutions
Fields
Rankings
Compare

Search institutions, scholars, countries and publications

Sankore

Named after the University of Sankore in Timbuktu — one of the world’s oldest centres of learning. Every figure here is computed from work-level records in our own graph, never copied from a source’s summary count.

Built from

OpenAlex — works, authorships, subject classification
ROR — institutional identity
ORCID — researcher identity
Crossref — publisher confirmation

Browse

Countries
Institutions
Fields
Rankings
What we cover

Coverage is partial and says so. A country appears with its research output only once its works have been swept; until then the portal shows whatever the graph happens to hold for it and labels it as exactly that.

Tsiri Agbenyega · Sankore

Kwame Nkrumah University of Science and Technology

Tsiri Agbenyega

Name matching only

This profile was assembled from author names on publications. Open indexes routinely split one researcher across several such profiles, so these totals may be incomplete.

Publications

10

Citations

230

h-index

5

Computed over the works the graph holds, so it is a floor rather than a career figure.

i10-index

5

Works published 2022 onward have been swept for this country. Figures are complete within that window, to the extent the open indexes are.

Affiliations

Every institution this scholar has appeared with on a work, by how many.

Kwame Nkrumah University of Science and Technology11 works
Presbyterian University, Ghana7 works
Komfo Anokye Teaching Hospital4 works

Publications

10 works in the graph, newest first.

Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9–14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trial
2025The Lancet Infectious DiseasesJournalOpen accessFirst author13 citations10.1016/s1473-3099(25)00031-3
Sustained efficacy of the RTS,S/AS01E malaria vaccine over 50 months of follow-up when used in full-dose or fractional-dose regimens in young children in Ghana and Kenya: final results from an open-label, phase 2b, randomised controlled trial
2025The Lancet Global HealthJournalOpen access3 citations10.1016/s2214-109x(25)00272-4
Feasibility, safety, and impact of the RTS,S/AS01E malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi
2024The LancetJournalOpen access89 citations10.1016/s0140-6736(24)00004-7
Safety and immunogenicity of Innovax bivalent human papillomavirus vaccine in girls 9–14 years of age: Interim analysis from a phase 3 clinical trial

2024

Vaccine

Journal

Open access

Senior author

23 citations

10.1016/j.vaccine.2024.02.077

Genotypic analysis of RTS,S/AS01E malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5–17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trial

2024The Lancet Infectious DiseasesJournalOpen access17 citations10.1016/s1473-3099(24)00179-8

Could Less Be More? Accounting for Fractional-Dose Regimens and Different Number of Vaccine Doses When Measuring the Impact of the RTS,S/AS01E Malaria Vaccine

2024The Journal of Infectious DiseasesJournalOpen access4 citations10.1093/infdis/jiae075

Detection of naturally acquired, strain-transcending antibodies against rosetting Plasmodium falciparum strains in humans

2024Infection and ImmunityJournalOpen access2 citations10.1128/iai.00015-24

Longitudinal associations of plasma amino acid levels with recovery from malarial coma

2024Malaria JournalJournalOpen access1 citations10.1186/s12936-024-05077-9

Prostration and the prognosis of death in African children with severe malaria

2023International Journal of Infectious DiseasesJournalOpen access3 citations10.1016/j.ijid.2023.06.022

Efficacy of RTS,S/AS01E malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5–17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial

2022The Lancet Infectious DiseasesJournalOpen access75 citations10.1016/s1473-3099(22)00273-0